Amyotrophic Lateral Sclerosis Pipeline Insights and Treatment Drugs 2024 (Updated)

DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Amyotrophic Lateral Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Amyotrophic Lateral Sclerosis research. Learn more about our innovative pipeline today! @ Amyotrophic Lateral Sclerosis Pipeline Outlook- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report
• In November 2024:- Woolsey Pharmaceuticals- The study population will consist of subjects with a diagnosis of probable laboratory-supported, probable, or definite ALS, as defined by El Escorial Revised ALS diagnostic criteria; with ALS symptom onset within 48 months; and with percent predicted SVC ≥ 50% at Screening 1. Subjects must also have an average rate of decline in ALSFRS-R at Screening 1 of 0.5 to 3.0 points/month, with rate of decline calculated using historical data (either prior ALSFRS-R score or date of ALS symptom onset).
• In November 2024:- Ionis Pharmaceuticals- A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS)
• In November 2024:- Rapa Therapeutics LLC- In the initial phase 1/2 study design, patients received therapy on Cohort 1 (low-dose RAPA-501; 20 x 10EE6 cells per infusion), Cohort 2 (high-dose RAPA-501; 80 x 10EE6 cells per infusion), and Cohort 3A (low-dose RAPA-501 when administered after a 3-day host conditioning regimen consisting of pentostatin plus cyclophosphamide. At the time of study amendment to add the expansion cohort, some patients already enrolled to the phase 1/2 aspect of the trial will continue to receive their initially designated cohort therapy and follow-up evaluation.
• DelveInsight's Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.
• The leading Amyotrophic Lateral Sclerosis Companies such as Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others.
• Promising Amyotrophic Lateral Sclerosis Therapies such as Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), ION363, and others.

Stay informed about the cutting-edge advancements in Amyotrophic Lateral Sclerosis treatments. Download for updates and be a part of the revolution in cancer care @ Amyotrophic Lateral Sclerosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Amyotrophic Lateral Sclerosis Emerging Drugs Profile
• MN-166: MediciNova
MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of ALS.
• RNS60: Revalesio
RNS60 is being developed to provide disease modifying and potentially restorative treatments for neurological diseases. The drug activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protects neurons and oligodendrocytes and modulates the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the US Food and Drug Administration. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.
• VM202: Helixmith
VM202 is an innovative gene therapy drug that provides fundamental treatment through tissue regeneration. The drug is injected along the peripheral nerves and their branches, the internal production of HGF may protect nerves and promote the growth of neurons while also ameliorating atrophic conditions. The US FDA granted orphan drug and fast track designation to VM202. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.
• QRL-201: QurAlis Corporation
QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in ALS patients. STMN2 is a well-validated protein important for neural repair and axonal stability, the expression of which is significantly decreased in nearly all ALS patients. QRL-201 rescues STMN2 loss of function in QurAlis ALS patient-derived motor neuron disease models in the presence of TDP-43 pathology. The drug is currently being evaluated under Phase I clinical trial for the Amyotrophic Lateral Sclerosis treatment.

Learn more about Amyotrophic Lateral Sclerosis Drugs opportunities in our groundbreaking Amyotrophic Lateral Sclerosis Research and development projects @ Amyotrophic Lateral Sclerosis Unmet Needs- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Amyotrophic Lateral Sclerosis treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Amyotrophic Lateral Sclerosis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Amyotrophic Lateral Sclerosis Pipeline Report
• Coverage- Global
• Amyotrophic Lateral Sclerosis Companies- Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others.
• Amyotrophic Lateral Sclerosis Therapies- Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), ION363, and others.
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Amyotrophic Lateral Sclerosis Pipeline on our website @ Amyotrophic Lateral Sclerosis Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. MN-166: MediciNova
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. QRL-201: QurAlis Corporation
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Amyotrophic Lateral Sclerosis Key Companies
21. Amyotrophic Lateral Sclerosis Key Products
22. Amyotrophic Lateral Sclerosis- Unmet Needs
23. Amyotrophic Lateral Sclerosis- Market Drivers and Barriers
24. Amyotrophic Lateral Sclerosis- Future Perspectives and Conclusion
25. Amyotrophic Lateral Sclerosis Analyst Views
26. Amyotrophic Lateral Sclerosis Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2024

cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
embolotherapy market- https://www.delveinsight.com/report-store/embolotherapy-market
keloid market- https://www.delveinsight.com/report-store/keloid-market
orthopedic power devices market- https://www.delveinsight.com/report-store/orthopedic-power-devices-market
shingles market- https://www.delveinsight.com/report-store/shingles-market
short bowel syndrome market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
testicular neoplasm market- https://www.delveinsight.com/report-store/testicular-cancer-market
dyspepsia market- https://www.delveinsight.com/report-store/dyspepsia-market
liquid biospy for cancer diagnostics market- https://www.delveinsight.com/report-store/liquid-biopsy-in-cancer-diagnostics-market
perennial allergic rhinitis market- https://www.delveinsight.com/report-store/perennial-allergic-rhinitis-market
plaque psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
polycystic ovarian syndrome market- https://www.delveinsight.com/report-store/polycystic-ovarian-syndrome-market
respiratory syncytial virus market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
sarcopenia market- https://www.delveinsight.com/report-store/sarcopenia-market
smoking cessation and nicotine addiction market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
catheter stabilization devices market- https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
nonalcoholic steatohepatitis market- https://www.delveinsight.com/blog/nonalcoholic-steatohepatitis-nash-highly-epidemic
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
pertussis market- https://www.delveinsight.com/report-store/pertussis-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
viscosupplementation devices market- https://www.delveinsight.com/report-store/viscosupplementation-devices-market
bacterial meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
cxcr inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
hdac inhibitors market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
plasmodium vivax malaria market- https://www.delveinsight.com/report-store/plasmodium-vivax-malaria-market
vascular access devices market- https://www.delveinsight.com/report-store/vascular-access-device-market
venous ulcer market- https://www.delveinsight.com/report-store/venous-leg-ulcer-market
ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/phototherapies-for-psoriasis-market
pulmonary emphysema market- https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
overactive bladder syndrome market- https://www.delveinsight.com/report-store/overactive-bladder-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
somatotropin deficiency market- https://www.delveinsight.com/report-store/somatotropin-deficiency-market
thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
tourette syndrome market- https://www.delveinsight.com/report-store/tourette-syndrome-market
external defibrillators market- https://www.delveinsight.com/report-store/defibrillator-market
plantar fasciitis market- https://www.delveinsight.com/report-store/plantar-fasciitis-market
scoliosis market- https://www.delveinsight.com/report-store/scoliosis-market
tendonitis market- https://www.delveinsight.com/report-store/tendonitis-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
peripheral nerve injuries market- https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market
sepsis market- https://www.delveinsight.com/report-store/sepsis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
consulting solutions- https://www.delveinsight.com/consulting
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
positive airway pressure device market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
TCR therapy market- https://www.delveinsight.com/report-store/t-cell-receptor-tcr-therapy-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
Nontuberculous Mycobacterial Market- https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market
intraocular lens market https://www.delveinsight.com/report-store/intraocular-lens-market
orthopedic splints device market- https://www.delveinsight.com/report-store/orthotic-devices-market
transcatheter treatment market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
NK cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
skin neoplasm market- https://www.delveinsight.com/blog/skin-cancer-treatment-market-and-key-companies
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.